⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19484440 | 1.00 | — | — | |
| SCHEMBL13660346 | 1.00 | — | — | |
| SCHEMBL17680350 | 0.97 | — | — | |
| SCHEMBL13805903 | 0.97 | — | — | |
| SCHEMBL12584756 | 0.97 | — | — | |
| SCHEMBL21479600 | 0.97 | — | — | |
| SCHEMBL16473090 | 0.87 | — | — | |
| SCHEMBL26710004 | 0.87 | — | — | |
| SCHEMBL13806340 | 0.84 | — | — | |
| SCHEMBL18057680 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230234948-A1 | CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234948-A1 | CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023091554-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023072974-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| US-20220306604-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20210387977-A1 | CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210387978-A1 | CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2021-12-16 | — | — | US | disclosed |
| WO-2021252818-A1 | CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2020123872-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |